Shots:

• The approval is based on three P-III studies results assessing Epidiolex (cannabidiol- PO) vs PBO in 516 patients with Lennox-Gastaut syndrome (LGS) or Dravet syndrome aged ≥ 2yrs.
• The study demonstrated in reduction in frequency of seizures
• Epidiolex (cannabidiol- PO) is an oral anti-epileptic drug and has received FDA’s PR- FT- & OD designation on 27 Jun- 2018- Jun- 2014- & 28 Feb- 2014 respectively and has also received EMA’s ODD for treating west syndrome & TSC

Ref: GW Pharmaceuticals | Image: Hempbizjournal